Korro Bio Rings the Nasdaq Stock Market Closing Bell

09:22Well, good afternoon everyone.

09:24I'm David Wicks, Vice President of Listings here at Nasdaq.

09:27It's truly my great pleasure to welcome bio and President and CEO Ramer.

09:34I'd also like to extend a very warm welcome to members of the coal bio executive team,

09:38the leadership team, family,

09:41employees, and all our distinguished guests to Nasdaq.

09:44We're excited. You could all join us right here at

09:47the crossroads of the world in Times Square, New York.

09:49As we get set to ring today's closing bell.

09:52Lot to celebrate. Lot to be thankful for.

09:55We're inside out of the cold.

09:58What do you think? Big round of applause Let's kick it off.

10:10Coro Bio is a bio pharmaceutical company

10:15focused on developing a new class of genetic medicines for

10:19both rare and highly prevalent diseases using

10:22its proprietary RNA editing platform By editing RNA instead of DNA.

10:28Coro is expanding the reach of genetic medicines by delivering additional precision,

10:34which has the potential for increased specificity and improve long term tolerability.

10:40Coro expects to bring its medicines to patients by leveraging

10:45its proprietary platform with precedented delivery modalities,

10:50manufacturing know how and established regulatory pathways.

10:54I know without a doubt this is a team effort.

10:57So I want to congratulate you and everyone at Coro on all that you've achieved together.

11:03We're exceptionally proud to be your partner and we look forward to supporting

11:07your continued growth and innovation as a Nasdaq listed company.

11:12Without further ado, please join me in welcoming Ram for his remarks.

11:21Wow, it's been a long time coming here.

11:26Thank you David and Nasdaq for having us here.

11:30It's a small milestone for us in this long journey that Ro is in developing medicines.

11:37So we'll chat this moment in the future.

11:41Each one of us has lost a loved one.

11:46Have tended to debiliting diseases for a friend or a loved one.

11:54In most of those cases,

11:57the origins of those disease is usually a combination of genetics,

12:03environmental factors, and lifestyle.

12:07We can work on lifestyle,

12:10we can work on the environmental factors.

12:13There are only certain instances where you can work on genetics.

12:18What if we can identify those individuals that have good genes?

12:25Learn from them, help us solve some of these more chronic diseases.

12:33Beyond that, what if you can design a drug that you can provide to

12:39these patients without touching DNA and provide benefit at the same level,

12:46transiently as any other drug that's currently on the market.

12:50That is what we're doing at Co,

12:53the specificity that David spoke about,

12:56the precision that David spoke about,

12:58that is what we aspire to at Corro in helping patients with chronic diseases.

13:04It is another milestone for us this year where in the later half of this year we will

13:10look to take our drug into the clinic and show and prove out this technology.

13:18This is a team effort.

13:20As you mentioned, it's a marathon.

13:22There are many people that have played a part here.

13:25I want to thank each and every one of them,

13:28The executive team, their families,

13:31the families of the employees.

13:34Finally, I would be remiss to mention

13:37my family and two daughters without which I would not be able to do here.

13:44Thank you all for all the support.

13:47Thank you all to our shareholders.

13:49Thank you all to our investors that have shown the confidence in the company to

13:55bring us to where we are back.

14:03Pro is literally the reason we exist and we're so proud of our partnership.

14:08And I know that you're going to be back to celebrate more milestones.

14:11But this afternoon, very proud to present

14:14you and your team with our closing bell crystals.

14:16Great, congratulations. Thank you so much.

14:18Thank you God, one you come.